These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26138106)

  • 1. Pheochromocytoma: Gasping for Air.
    Jochmanová I; Zhuang Z; Pacak K
    Horm Cancer; 2015 Dec; 6(5-6):191-205. PubMed ID: 26138106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
    Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.
    Lehtonen HJ; Mäkinen MJ; Kiuru M; Laiho P; Herva R; van Minderhout I; Hogendoorn PC; Cornelisse C; Devilee P; Launonen V; Aaltonen LA
    Int J Cancer; 2007 Sep; 121(6):1386-9. PubMed ID: 17520677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.
    Nölting S; Grossman AB
    Endocr Pathol; 2012 Mar; 23(1):21-33. PubMed ID: 22391976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
    Jochmanová I; Yang C; Zhuang Z; Pacak K
    J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pheochromocytoma: The First Metabolic Endocrine Cancer.
    Jochmanova I; Pacak K
    Clin Cancer Res; 2016 Oct; 22(20):5001-5011. PubMed ID: 27742786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
    Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
    Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
    Vicha A; Musil Z; Pacak K
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting NAD
    Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
    Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma.
    Kluckova K; Tennant DA
    Cell Tissue Res; 2018 May; 372(2):367-378. PubMed ID: 29450727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas.
    Remacha L; Comino-Méndez I; Richter S; Contreras L; Currás-Freixes M; Pita G; Letón R; Galarreta A; Torres-Pérez R; Honrado E; Jiménez S; Maestre L; Moran S; Esteller M; Satrústegui J; Eisenhofer G; Robledo M; Cascón A
    Clin Cancer Res; 2017 Oct; 23(20):6315-6324. PubMed ID: 28720665
    [No Abstract]   [Full Text] [Related]  

  • 12. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.
    Job S; Draskovic I; Burnichon N; Buffet A; Cros J; Lépine C; Venisse A; Robidel E; Verkarre V; Meatchi T; Sibony M; Amar L; Bertherat J; de Reyniès A; Londoño-Vallejo A; Favier J; Castro-Vega LJ; Gimenez-Roqueplo AP
    Clin Cancer Res; 2019 Jan; 25(2):760-770. PubMed ID: 30301828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors.
    Jochmanová I; Zelinka T; Widimský J; Pacak K
    Physiol Res; 2014; 63(Suppl 2):S251-62. PubMed ID: 24908231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene.
    Cascón A; Comino-Méndez I; Currás-Freixes M; de Cubas AA; Contreras L; Richter S; Peitzsch M; Mancikova V; Inglada-Pérez L; Pérez-Barrios A; Calatayud M; Azriel S; Villar-Vicente R; Aller J; Setién F; Moran S; Garcia JF; Río-Machín A; Letón R; Gómez-Graña Á; Apellániz-Ruiz M; Roncador G; Esteller M; Rodríguez-Antona C; Satrústegui J; Eisenhofer G; Urioste M; Robledo M
    J Natl Cancer Inst; 2015 Mar; 107(5):. PubMed ID: 25766404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma.
    Mannelli M; Rapizzi E; Fucci R; Canu L; Ercolino T; Luconi M; Young WF
    Endocr Relat Cancer; 2015 Aug; 22(4):T83-90. PubMed ID: 26113605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy.
    Pacak K; Kidd M; Meuter L; Modlin IM
    Endocr Relat Cancer; 2021 Oct; 28(11):731-744. PubMed ID: 34515661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.
    Fliedner SM; Kaludercic N; Jiang XS; Hansikova H; Hajkova Z; Sladkova J; Limpuangthip A; Backlund PS; Wesley R; Martiniova L; Jochmanova I; Lendvai NK; Breza J; Yergey AL; Paolocci N; Tischler AS; Zeman J; Porter FD; Lehnert H; Pacak K
    PLoS One; 2012; 7(7):e40949. PubMed ID: 22859959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency.
    Favier J; Brière JJ; Strompf L; Amar L; Filali M; Jeunemaitre X; Rustin P; Gimenez-Roqueplo AP;
    Horm Res; 2005; 63(4):171-9. PubMed ID: 15795514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
    Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
    Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.